CClinicalTrials.gg
RecruitingNCT06989164Updated Dec 2, 2025

Post Prandial Individual Responses to Different Foods

An interventional study of Post prandial testing in PreDiabetes, Diabetes Mellitus, Type 2 and Healthy, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to understand why people respond differently to the same foods, especially when it comes to changes in blood sugar after eating. A continuous glucose monitors (CGMs) will be used to observe how individuals respond to specific meals and drinks (e.g., Oral Glucose Tolerance Test, OGTT). By studying these patterns, the investigators hope to identify different types of metabolism and see if certain foods or food ingredients (like fiber, amino acids, or vinegar) can help control blood sugar better for specific groups. This research will help lay the groundwork for personalized dietary advice based on a person's unique biology.

Read the detailed description

Participants in the study will be provided with a continuous glucose monitor (CGM) and pre-measured cooked rice to test with different potential mitigators: fiber, acid, amino acid (e.g., leucine), whole protein, and exercise. Each of these conditions will be tested on a different day following strict instructions. For some of these tests, participants will be asked to collect a blood microsample and a saliva sample before and after eating the test meal. A stool sample will be collected at baseline.

02

Conditions studied

  • PreDiabetes
  • Diabetes Mellitus, Type 2
  • Healthy
03

In context

Prediabetic State

999 studies on the registry are indexed under Prediabetic State; 238 are open to participants now.

This study's planned enrollment of 100 is above the median of 65 across 844 interventional studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • BMI (body mass index) >19 kg/m2 but \< 45 kg/m2
  • HbA1c \< or equal to 7.0% while not on antihyperglycemic medications
  • Be willing to provide written informed consent for all study procedures.
  • Able to commute to Stanford campus for on-site visits

Exclusion criteria

Exclusion Criteria:

  • recent (\<6mos) CVD (cardiovascular disease) event
  • active malignancy
  • kidney/liver disease
  • pregnancy/lactation
  • chronic inflammatory disease
  • eating disorder
  • bariatric surgery
  • history of acute pancreatitis
  • current use of antihyperglycemic, diabetogenic, or weight loss medications
  • heavy alcohol use
  • physical activity >2 hours/day
  • inability to come to Stanford CTRU (Clinical and Translational Research Unit) for metabolic testing
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Diet Cycles

    Participants will be asked to consume pre-portioned foods on different days as the first meal of the day, use a CGM, and take saliva and micro samples of blood before and after each meal.

    Other: Post prandial testing

Interventions

  • OtherPost prandial testing

    A variety of foods, supplements, and short prescriptive exercise will be tested to see which one helps mitigate the rise is postprandial glucose after eating carbohydrate containing foods.

06

What researchers measure

Primary outcomes

  1. Post prandial peak glucose levels

    Delta glucose peak within 3 hours after consuming the standard meal - peak glucose value minus baseline glucose value at time 0 measured by CGM in mg/dL.

    Time frame: 3 hours

  2. Post prandial glucose area under the curve (AUC)

    AUC (\>baseline) within three hours measured by CGM in mg/dL during the 3 hours after each study meal.

    Time frame: 3 hours

Secondary outcomes

  1. Glucose time to peak

    The time in minutes from baseline to peak within 3 hours measured by CGM after each standardized meal.

    Time frame: 3 hours

  2. Changes in personal post prandial metabolic states as measured in micro-sampling by targeted and untargeted metabolomics (LC-MS)

    Dry blood samples will be collected by micro-sampling before and 1 hour after the standardized meals. Based on those samples, metabolomics (e.g., short-chain fatty acids, amino acids and other polar and nonpolar metabolites) will be extracted and quantified by liquid chromatography mass spectrometry (LC-MS). Both hydrophilic LC and reverse phase LC will be used. Q Exactive will be used for MS. Tandem MS will be collected for annotation. Relative quantification will be used, where the level of metabolites can be compared between samples. Chemical reference will be used for the absolute quantification of targeted metabolites.

    Time frame: 1 hour

  3. Individual microbiome composition

    Microbiome will be defined by using metagenomics assay to baseline samples

    Time frame: Baseline

  4. Changes in postprandial proteomic responses as measured in micro-sampling by Olink

    Dry blood samples will be collected by micro-sampling frequently before and after the standardized meals. Based on those samples, proteomics will be quantified by proximity extension assay for the cardiometabolic panel. 96 proteins will be measured in the unit of normalized protein expression.

    Time frame: 1 hour

07

Study locations

1 of 1 sites recruiting
  • Stanford University
    Stanford, California 94304, United States
    • Sabrina Chun Johnston, MS, RD · Contact · csjohn@stanford.edu · (650) 725-0169
    • Dalia Perelman, MS, RD, CDE · Sub investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The investigator plan to share de-identified data to both public repositories and integrated databases when the consent of data sharing is obtained. The analysis results will be shared with the publication.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06989164
Lead sponsor
Stanford University
Responsible party
Yue Wu (Post doctoral, Stanford University) — Principal investigator
First posted
May 25, 2025
Start date
Oct 1, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Dec 2, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion